Article ; Online: The role of histone H3 lysine demethylases in glioblastoma.
2023 Volume 42, Issue 2, Page(s) 445–454
Abstract: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with an average survival of 15-18 months. Part of its malignancy derives from epigenetic regulation that occurs as the tumor develops and after therapeutic treatment. Specifically, ... ...
Abstract | Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with an average survival of 15-18 months. Part of its malignancy derives from epigenetic regulation that occurs as the tumor develops and after therapeutic treatment. Specifically, enzymes involved in removing methylations from histone proteins on chromatin, i.e., lysine demethylases (KDMs), have a significant impact on GBM biology and reoccurrence. This knowledge has paved the way to considering KDMs as potential targets for GBM treatment. For example, increases in trimethylation of histone H3 on the lysine 9 residue (H3K9me3) via inhibition of KDM4C and KDM7A has been shown to lead to cell death in Glioblastoma initiating cells. KDM6 has been shown to drive Glioma resistance to receptor tyrosine kinase inhibitors and its inhibition decreases tumor resistance. In addition, increased expression of the histone methyltransferase MLL4 and UTX histone demethylase are associated with prolonged survival in a subset of GBM patients, potentially by regulating histone methylation on the promoter of the mgmt gene. Thus, the complexity of how histone modifiers contribute to glioblastoma pathology and disease progression is yet to be fully understood. To date, most of the current work on histone modifying enzymes in GBM are centered upon histone H3 demethylase enzymes. In this mini-review, we summarize the current knowledge on the role of histone H3 demethylase enzymes in Glioblastoma tumor biology and therapy resistance. The objective of this work is to highlight the current and future potential areas of research for GBM epigenetics therapy. |
---|---|
MeSH term(s) | Humans ; Histones/genetics ; Histones/metabolism ; Histone Demethylases/genetics ; Histone Demethylases/metabolism ; Glioblastoma/genetics ; Glioblastoma/pathology ; Lysine/genetics ; Lysine/metabolism ; Epigenesis, Genetic ; Jumonji Domain-Containing Histone Demethylases/genetics ; Jumonji Domain-Containing Histone Demethylases/metabolism |
Chemical Substances | Histones ; Histone Demethylases (EC 1.14.11.-) ; Lysine (K3Z4F929H6) ; KDM4C protein, human ; Jumonji Domain-Containing Histone Demethylases (EC 1.14.11.-) ; KDM7A protein, human (EC 1.14.11.-) |
Language | English |
Publishing date | 2023-06-08 |
Publishing country | Netherlands |
Document type | Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't |
ZDB-ID | 604857-2 |
ISSN | 1573-7233 ; 0167-7659 |
ISSN (online) | 1573-7233 |
ISSN | 0167-7659 |
DOI | 10.1007/s10555-023-10114-1 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1812: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.